7,051 results match your criteria Retinal Vein Occlusion


Correlation between change in central subfield thickness and change in visual acuity in macular edema due to retinal vein occlusion: post hoc analysis of COPERNICUS, GALILEO, and VIBRANT.

Graefes Arch Clin Exp Ophthalmol 2022 Jun 24. Epub 2022 Jun 24.

Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Purpose: Assess correlation between change in central subfield thickness (CST) and change in best-corrected visual acuity (BCVA) in eyes with macular edema due to retinal vein occlusion (RVO) that received intravitreal aflibercept injections (IAI).

Methods: Post hoc analysis of COPERNICUS and GALILEO trials for CRVO and VIBRANT trial for BRVO with relationships determined using Pearson correlation coefficient.

Results: In COPERNICUS, correlations (r) between change in CST and change in BCVA from baseline at weeks 12, 24, 52, and 100 were -0. Read More

View Article and Full-Text PDF

Foveal Intraretinal Fluid Localization Affects the Visual Prognosis of Branch Retinal Vein Occlusion.

J Clin Med 2022 Jun 20;11(12). Epub 2022 Jun 20.

Department of Ophthalmology, Shinseikai Toyama Hospital, Imizu 939-0243, Japan.

We investigated whether baseline foveal intraretinal fluid (IRF) localization affects the visual prognosis of branch retinal vein occlusion (BRVO). Fifty eyes from 50 patients were included in this retrospective study. We classified the eyes with IRF involving and not involving the central foveola on the vertical optical coherence tomography (OCT) image at the initial visit into both-sides ( = 17) and one-side IRF ( = 33) groups, respectively. Read More

View Article and Full-Text PDF

Vision-Threatening Ocular Adverse Events after Vaccination against Coronavirus Disease 2019.

J Clin Med 2022 Jun 9;11(12). Epub 2022 Jun 9.

Department of Ophthalmology, Korea University Guro Hospital, Korea University Medicine, 148, Gurodong-ro, Guro-gu, Seoul 08308, Korea.

A single-center retrospective observational case series was conducted. This case series enrolled patients who showed ophthalmic manifestations within one week after COVID-19 vaccination at Korea University Guro Hospital in Seoul, Korea, from May 2021 to January 2022. The medical records of patients who complained of ocular symptoms and showed ophthalmic adverse events within one week after COVID-19 vaccination were reviewed. Read More

View Article and Full-Text PDF

Retinal vascular occlusion in patients with the Covid-19 virus.

Int J Retina Vitreous 2022 Jun 23;8(1):45. Epub 2022 Jun 23.

Fundacao Universidade Regional de Blumenau, Rua Antonio Veiga 140, Blumenau (SC), ZIP: 89030-903, Brazil.

Background: The coronavirus disease (COVID-19) can cause acute respiratory distress syndrome with dyspnea, anosmia, fever, and cough. Few studies describing ocular findings have been reported. The current case series, reports the clinical findings and natural history of patients with retinal vascular occlusion after COVID-19 infection. Read More

View Article and Full-Text PDF

Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology.

Sci Rep 2022 Jun 17;12(1):10162. Epub 2022 Jun 17.

Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.

Despite many studies, optimal treatment sequences or intervals are still questionable in retinal vein occlusion (RVO) macular edema. The aim of this study was to examine the real-world treatment patterns of RVO macular edema. A retrospective analysis of the Observational Medical Outcomes Partnership Common Data Model, a distributed research network, of four large tertiary referral centers (n = 9,202,032) identified 3286 eligible. Read More

View Article and Full-Text PDF

Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma.

BMC Ophthalmol 2022 Jun 20;22(1):270. Epub 2022 Jun 20.

Department of Ophthalmology, School of Medicine, Kyungpook National University, 680 gukchaebosang-ro, Jung-gu, Daegu, 41944, South Korea.

Background: We evaluated the long-term efficacy and surgical outcomes of Ahmed glaucoma valve (AGV) implantation in patients with refractory glaucoma by glaucoma type.

Methods: In total, 135 eyes of 135 patients diagnosed with refractory glaucoma and underwent AGV implantation between 2002 and 2018 were reviewed retrospectively. The best-corrected visual acuity (BCVA), intraocular pressure (IOP), and number of antiglaucoma medications were investigated at baseline and follow-up. Read More

View Article and Full-Text PDF

Novel Association between Opioid Use and Increased Risk of Retinal Vein Occlusion Using the National Institutes of Health Research Program.

Ophthalmol Sci 2022 Mar 20;2(1). Epub 2021 Dec 20.

Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California.

Purpose: To assess for risk factors for retinal vein occlusion (RVO) among participants in the National Institutes of Health database, particularly social risk factors that have not been well studied, including substance use.

Design: Retrospective, case-control study.

Participants: Data were extracted for 380 adult participants with branch retinal vein occlusion (BRVO), 311 adult participants with central retinal vein occlusion (CRVO), and 1520 controls sampled among 311 640 adult participants in the database. Read More

View Article and Full-Text PDF

XEN 63 gel stent to treat a refractory uveitic glaucoma: A case report.

Eur J Ophthalmol 2022 Jun 16:11206721221109199. Epub 2022 Jun 16.

386696Service d'Ophtalmologie, 423788Hôpital de la Croix-Rousse, Hospices Civils de Lyon, France.

Purpose: To describe the effectiveness of the XEN 63 gel stent in a refractory uveitic glaucoma after failure of an Ahmed Glaucoma Valve.

Case Description: We report the case of a 54-year-old man with a history of uveitic glaucoma on his left eye due to Fuchs heterochromic iridocyclitis and neovascular glaucoma after a central retinal vein occlusion. Pre-operative intraocular pressure was 30 mmHg despite a QD (once-daily) dosed bimatoprost 0. Read More

View Article and Full-Text PDF

Clinical Features of Central Retinal Vein Occlusion in Young Patients.

Ophthalmol Ther 2022 Jun 13. Epub 2022 Jun 13.

Department of Ophthalmology, The First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang, 110001, China.

Retinal vein occlusion (RVO) is the second most common retinal vascular disease. Central RVO (CRVO), in which obstruction occurs posterior to the lamina cribrosa due to various causes, manifests with extensive venous tortuosity, dilatation of blood vessels in the four quadrants, and retinal hemorrhage. The presence of macular edema decreases visual acuity in patients with CRVO, especially in elderly patients with hypertension, hyperlipidemia, and diabetes. Read More

View Article and Full-Text PDF

Potential Prognostic Indicators for Patients With Retinal Vein Occlusion.

Front Med (Lausanne) 2022 25;9:839082. Epub 2022 May 25.

Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

The second most prevalent cause of retinal vascular disease is retinal vein occlusion (RVO). RVO raises intravascular pressure in the capillary and veins, triggering vessel barrier collapse and subsequent leaking of blood or plasma components into the tissue (edema). Macular edema (ME) is a major complication of RVO that results in significant visual impairment. Read More

View Article and Full-Text PDF

Evaluation of Systemic Endothelial Dysfunction in Retinal Vein Occlusions.

Beyoglu Eye J 2022 27;7(2):126-133. Epub 2022 May 27.

Department of Cardiology, Kafkas University, Kars, Turkey.

Objectives: Our aim in this study was to evaluate the systemic endothelial dysfunction status and carotid intima-media thickness (CIMT) in patients with retinal vein occlusion (RVO).

Methods: Seventy-six patients who presented to the clinic with the diagnosis of RVO and 76 age- and gender-matched healthy individuals without a RVO history were included in the study. The patients' best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measures, and diabetes, hypertension, hyperlipidemia, carotid artery disease, body mass index, and smoking histories were recorded. Read More

View Article and Full-Text PDF

Combined intravitreal injection of bevacizumab and a ROCK inhibitor (fasudil) for refractory macular edema secondary to retinal vein occlusion: a pilot study.

Int J Retina Vitreous 2022 Jun 11;8(1):37. Epub 2022 Jun 11.

Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, No 23, Paidarfard St., Boostan 9 St., Pasdaran Ave, Tehran, 16666, Iran.

Background: To investigate the adjunctive effect of an intravitreal ROCK inhibitor (fasudil) in combination with intravitreal bevacizumab (IVB) on refractory macular edema secondary to retinal vein occlusion (RVO).

Methods: In this prospective interventional case series, 17 eyes of 17 patients (10 men, 7 women) with refractory RVO-related macular edema underwent three consecutive intravitreal injections of bevacizumab plus fasudil. Monthly evaluation was continued up to 12 months and IVB injection was performed if needed during the follow-up. Read More

View Article and Full-Text PDF

Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion.

Molecules 2022 May 24;27(11). Epub 2022 May 24.

Department of Ophthalmology, Aalborg University Hospital, 9000 Aalborg, Denmark.

Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO). Retinal proteome changes following aflibercept intervention in CRVO remain largely unstudied. Studying proteomic changes of aflibercept intervention may generate a better understanding of mechanisms of action and uncover aspects related to the safety profile. Read More

View Article and Full-Text PDF

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema.

BMC Ophthalmol 2022 Jun 4;22(1):247. Epub 2022 Jun 4.

Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.

Background: Patients with central retinal vein occlusion (CRVO) and macular edema often are treated by intravitreal ranibizumab injection (IRI). The role of changes in macular sensitivity in the positive effects of IRI on visual functions is unclear. Therefore, we assessed the relationship between macular sensitivity and improvement of visual functions. Read More

View Article and Full-Text PDF

Paeoniflorin alleviates the progression of retinal vein occlusion via inhibiting hypoxia inducible factor-1α/vascular endothelial growth factor/STAT3 pathway.

Bioengineered 2022 05;13(5):13622-13631

Department of Ophthalmology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Retinal vein occlusion (RVO) is a severe retinal vascular disease involving several complications, leading to weakening of vision and even blindness. Globally, over 16 million patients with RVO were found in the middle-aged population. Paeoniflorin (PF), a monomer of Taohong Siwu decoction, was reported to exhibit many pharmacological activities including anti-inflammatory, antioxidant, cardioprotective, and neuroprotective effects. Read More

View Article and Full-Text PDF

COVID-19 AdenoviralVector Vaccine and Central Retinal Vein Occlusion.

Ocul Immunol Inflamm 2022 Jun 2:1-3. Epub 2022 Jun 2.

Eye Clinic, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Purpose: The purpose of this article is to report a case of sudden onset ischemic retinal central vein occlusion after a second dose of COVID-19 adenoviral vector vaccine.

Case Report/observations: A 54-year-old woman with systemic arterial hypertension developed ischemic central retinal vein occlusion in her right eye on day 2 after the second dose of COVID-19 adenoviral vector vaccine ChAdOx1 nCoV-19/ AZD1222, Oxford-AstraZeneca.

Conclusion: Adenoviral vector vaccine promotes both cellular and humoral immune responses, increasing the level of inflammatory cytokines. Read More

View Article and Full-Text PDF

Nasal vein occlusion after COVID-19: A case report.

Indian J Ophthalmol 2022 Jun;70(6):2195-2196

Department of Ophthalmology, Atatürk Educating and Research Hospital, İzmir Katip Çelebi University, Hatay, Izmir, Turkey.

To present a case of nasal vein occlusion that has not been reported after the coronavirus disease 2019 (Covid-19) pandemic. A 53-year-old patient reported a complaint of floaters after a recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. His best corrected visual acuity (BCVA) was 20/20 for both the eyes. Read More

View Article and Full-Text PDF

Retinal venous occlusion following COVID-19 vaccination: Report of a case after third dose and review of the literature.

Indian J Ophthalmol 2022 Jun;70(6):2191-2194

Department of Vitreoretina, Medical and Vision Research Foundations, Sankara Nethralaya, Sankara Nethralaya, Chennai, Tamil Nadu, India.

A 28-year-old, healthy male presented with blurring of vision in the right eye following third dose of the AstraZeneca/COVISHIELD vaccine. Further examination revealed ischemic central retinal vein occlusion, and subsequent laboratory investigations were inconclusive for his eye disease. He responded to pulse corticosteroid and tapering doses of oral corticosteroids without requiring any intra-vitreal injection. Read More

View Article and Full-Text PDF

Identifying the correct diagnosis on multimodal imaging for retinal vascular diseases.

Authors:
Sunny Chi Lik Au

QJM 2022 May 26. Epub 2022 May 26.

Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong.

View Article and Full-Text PDF

Retinal Vessel Density and Treatment Intensity among Adults with Retinal Vein Occlusion: A Swept-Source Optical Coherence Tomography Angiography Study.

J Clin Med 2022 May 20;11(10). Epub 2022 May 20.

Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Previous studies have shown retinal vein occlusion (RVO) is associated with changes in vessel density visible on swept-source optical coherence tomography angiography (ss-OCTA). This study aimed to characterize retinal changes on ss-OCTA among RVO patients stratified by the need for continuous anti-VEGF therapy. This cross-sectional study of 24 RVO patients ≥ 18 years were imaged with SS-OCT-A. Read More

View Article and Full-Text PDF

Bilateral Central Retinal Vein Occlusion and Stevens-Johnson Syndrome Associated with Coronavirus-19: A Case Report.

J Curr Ophthalmol 2022 Jan-Mar;34(1):121-123. Epub 2022 Apr 16.

Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.

Purpose: To report a case of bilateral central retinal vein occlusion (CRVO) associated with coronavirus-19 (COVID-19) infection.

Methods: A 43-year-old man presented to the emergency department with flu-like symptoms, severe erythema, a rash on his face, and respiratory distress. He was admitted to the intensive care unit, and the reverse transcriptase-polymerase chain reaction test was positive for the severe acute respiratory syndrome coronavirus-2 virus. Read More

View Article and Full-Text PDF

Retinal vein occlusion in patients under 50 years. Analysis of vascular risk factors, thrombophilia, carotid ultrasound findings and uncommon aetiologies.

Arch Soc Esp Oftalmol (Engl Ed) 2022 May 23. Epub 2022 May 23.

Departmento de Medicina Interna, Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain.

Introdution: Retinal vein occlusion (RVO) has been related to vascular risk factors and thrombophilia.

Methods: This is a prospective cohort study of all patients diagnosed with RVO and referred to an Internal Medicine clinic of a tertiary teaching hospital during a 10-year period. Clinical, laboratory and supra-aortic trunks ultrasound variables were analysed and compared according to age. Read More

View Article and Full-Text PDF

A One-Step Electrochemical Aptasensor Based on Signal Amplification of Metallo Nanoenzyme Particles for Vascular Endothelial Growth Factor.

Front Bioeng Biotechnol 2022 9;10:850412. Epub 2022 May 9.

Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.

In this study, a one-step electrochemical aptasensor was developed to detect the biomarker vascular endothelial growth factor (VEGF), an important protein in the pathogenesis of many retinal diseases, including age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, and retinal vein occlusion. The aptamer has a good affinity and can rapidly identify and capture VEGF based on its unique structure. We designed a VEGF aptasensor based on the aptamer recognition and complex metallo nanoenzyme particles as an electron exchange center and bridge between capture DNA and electrode. Read More

View Article and Full-Text PDF

Navigated laser and aflibercept versus aflibercept monotherapy in treatment-naïve branch retinal vein occlusion: A 12-month randomized trial.

Acta Ophthalmol 2022 May 25. Epub 2022 May 25.

Department of Ophthalmology, Odense University Hospital, Odense, Denmark.

Purpose: Angiostatic agents have proven effective in the treatment of macular oedema in patients with branch retinal vein occlusion (BRVO). However, treatment is inconvenient and expensive, and novel treatment regimens are warranted. We aimed to evaluate if combination treatment of navigated central retinal laser and aflibercept lowered the treatment burden in these patients. Read More

View Article and Full-Text PDF

Central Retinal Vein Occlusion Associated with Fibromuscular Dysplasia: A Case Report.

Case Rep Ophthalmol 2022 Jan-Apr;13(1):179-184. Epub 2022 Mar 17.

Department of Ophthalmology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

In this report, we detail a rare presentation of central retinal vein occlusion (CRVO) in a patient with fibromuscular dysplasia (FMD). A 45-year-old woman with a 12-year history of FMD presented to the ophthalmology clinic with symptoms and exam findings consistent with CRVO. Dilated fundus examination revealed disc edema, diffuse flame, and dot-blot hemorrhages, and tortuous, engorged retinal veins. Read More

View Article and Full-Text PDF

Recurrent Branch Retinal Artery Occlusions.

J Neuroophthalmol 2022 06;42(2):e527

Departments of Ophthalmology and Neurology, Mayo Clinic, Rochester, Minnesota.

View Article and Full-Text PDF

Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.

Ophthalmol Retina 2022 May 16. Epub 2022 May 16.

The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, New South Wales, Australia.

Purpose: To report the estimated incidence, probability, risk factors and one-year outcomes of rhegmatogenous retinal detachment (RRD) in eyes receiving intravitreal injections (IVT) of vascular endothelial growth factor (VEGF) inhibitors for various retinal conditions in routine clinical practice.

Design: Retrospective analysis of data from a prospectively designed observational outcomes registry: the Fight Retinal Blindness!

Project:

Participants: Eyes starting IVT with VEGF inhibitors (ranibizumab, aflibercept or bevacizumab) for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) or retinal vein occlusion (RVO) from 1 January 2006 to 31 December 2020. All eyes that developed RRD within 90 days of an intravitreal injection were defined as RRD cases and were matched with control eyes. Read More

View Article and Full-Text PDF

Association between proteinuria and retinal vein occlusion in individuals with preserved renal function: a retrospective cohort study.

Acta Ophthalmol 2022 May 17. Epub 2022 May 17.

Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan.

Purpose: To investigate the association between proteinuria and the incidence of retinal vein occlusion (RVO) in individuals with preserved renal function.

Methods: We conducted a retrospective cohort study from 2005 to 2020 using the JMDC Claims Database, a large database of health check-ups and administrative claims in Japan. Individuals who underwent annual health check-ups were included. Read More

View Article and Full-Text PDF

Isolated and combined unilateral central retinal artery and vein occlusions after vaccination. A review of the literature.

J Stroke Cerebrovasc Dis 2022 May 12;31(8):106552. Epub 2022 May 12.

Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong. Electronic address:

View Article and Full-Text PDF

Idiopathic combined retinal vessels occlusion in a pregnant woman: a case report.

J Med Case Rep 2022 May 15;16(1):191. Epub 2022 May 15.

Obstetrics and Gynecology Department, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Background: Ocular vascular occlusion is an extremely rare event, especially in the young population. This diagnosis is always associated with active systemic diseases in young adults and needs thrombophilia workup. Nevertheless, we present the case of a pregnant woman suffering from idiopathic combined central retinal vein and cilioretinal artery occlusion. Read More

View Article and Full-Text PDF